Also, our study reveals crosstalk between HER2 and SMO: Combining trastuzumab with Hh inhibitors (Vis or Cyc) synergistically suppresses SMO, further inactivating AKT/mTOR signalling and enhancing anti-tumour effects. Here, MTOR is linked to neoplasm.